Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Avivagen Inc V.VIV

Alternate Symbol(s):  VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


TSXV:VIV - Post by User

Bullboard Posts
Post by calderneton Apr 10, 2017 8:38am
271 Views
Post# 26099326

News - "Positive Proof of Concept"

News - "Positive Proof of Concept"Avivagen Reports Positive Proof of Concept in Preventing C. Difficile Infection

OTTAWA, April 10, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (VIV.V) (OTC Pink:CHEXF) (Avivagen or the Corporation), a company with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces positive results from a proof-of-concept study that could extend Avivagen’s OxC-beta™ technology into human health applications....

Read More at:
https://finance.yahoo.com/news/avivagen-reports-positive-proof-concept-114330077.html

Bullboard Posts